Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HitGen Inc.
The deal marks the biggest out-licensing agreement ever for Chong Kun Dang, with the Swiss giant poised to explore the novel small molecule in various cardiovascular indications.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
- Contract Research Organization-CRO
- Antisense, Oligonucleotides
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- HitGen Pharmaceuticals Inc., Vernalis (R&D) Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.